News

No doubt, my retina colleagues are way ahead of me in considering this issue. Reducing the frequency of injections by developing longer-lasting therapeutic agents and reducing the per-injection risk by careful scrutiny of evidence to determine the best practice when it comes to injection protocols are two possibilities.

Today’s laser cataract surgery is outperforming the early days of phacoemulsification and may outperform current phacoemulsification technology in the next few years, explained Yassine Daoud, MD, in a dialogue about the technology.

Cataract surgery lowers IOP in eyes with exfoliation syndrome (XFS) or exfoliation glaucoma (XFG), and it might even change the natural history of glaucoma in eyes with XFS. However, it may also be appropriate to combine phacoemulsification with glaucoma surgery in certain patients with XFG.

Toric IOL implantation using a proprietary image-guided system for planning and executing cataract surgery results in good accuracy to cylinder and MRSE targets.

Rho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.

A calcium channel blocker may be associated with marginal pupil dilation, making it more likely that pupil-dilating devices will be needed during phacoemulsification.

A new phacoemulsification system offers surgical functionality, features, and technology in a compact form factor.

One-year outcomes with a subretinal implant for patients blinded by retinitis pigmentosa demonstrated a marked improvement in visual capabilities.

Dropless cataract surgery-a combination of anti-infective and anti-inflammatory drugs injected transzonularly or through the pars plana for deposit into the vitreous-reduces the need for topical postoperative drops.

The Laser Cataract Consortium, comprising five experienced laser cataract surgeons, undertook a study incorporating rigorous collection of data from 7,200 eyes undergoing cataract surgery.

The eyewear market is changing more rapidly than ever, and it is no longer acceptable to sell the same way to each consumer. Staying up-to-date on how to leverage unique marketing to every generation is the key to success.

In her latest blog, Joy Gibb, ABOC, solves the much avoided topic of handling your most stubborn patients.

Did your state make the list?

One surgeon’s experiences with the iStent trabecular micro bypass; an implant that forms a patent opening through the trabecular meshwork into Schlemm’s canal, restoring physiological aqueous outflow and providing a significant and sustained decrease in IOP.

Bleb failure can often be avoided with well-managed trabeculectomy and effective postoperative care.

In this article, Dr Johannson presents intraindividual IOL comparison follow-up results. Although similar levels of PCO development were observed for both AcrySof and Tecnis one-piece IOLs, fewer glistenings appeared in the Tecnis material, 3 years after implantation.

A protein called PKal (plasma kallikrein) and its associated molecules are key players in an inflammatory molecular pathway involved in diabetic macular edema, according to a study published in Diabetes.

A gaming headset is helping researchers address balance issues in patients who have glaucoma.

An interventional trial recently compared standard and navigated pattern PRP techniques. In this article, Dr Kozak explains how continuous prepositioning and stabilisation of the aiming beam with navigated PRP, enables pattern application of the more effective longer pulse durations while reducing treatment times and broadens therapeutic options in proliferative diabetic retinopathy.

In this article, Dr Tanna discusses treatment options for glaucoma patients who do not show satisfactory response to a PGA while taking into consideration the two key therapeutic choice factors: IOP-lowering efficacy and tolerability.

This follow-up study found anterior capsule opacification development and anterior capsule retraction to be more frequent 3 years after cataract surgery when an IOL with interrupted sharp optic edge at the optic–haptic junction is implanted, compared with an IOL with a continuous edge.

CO2 laser-assisted sclerectomy surgery performed with a proprietary platform offers an effective and safer alternative to the manual non-penetrating deep sclerectomy procedure for the management of medically uncontrolled open-angle glaucoma.

In this comparison study, IOP reductions were greater with BTFC than with TTFC and patients on this combination were more likely to achieve and maintain low target pressures. Combined BrTFC and DTFC may also be a more appropriate therapeutic choice for IOP lowering than TTFC and BrTFC, respectively.

One-year after implantation of the Cypass Micro-Stent, study results demonstrate a reduction in IOP and glaucoma medications, as well as a complete lack of sight-threatening adverse events. The implant is placed into the supraciliary space to facilitate suprachoroidal aqueous outflow in glaucoma patients.

Using a new metric seems to be an easy way to determine a patient’s risk of developing ectasia after a refractive procedure, according to Marcony R. Santhiago, MD, PhD.

Ophthalmologists are over-prescribing steroids to treat vernal keratoconjunctivitis (VKC) and causing an increase of steroid-induced glaucoma (SIG) in children, according to a recent study publish in the British Journal of Ophthalmology.

Learn about the effect of increased osmolarity on the corneal surface. This video provides insight into managing patients with hyperosmolarity and about the importance of testing in patients considering surgery.

In his latest blog, Mark Packer, MD, writes of a surgical tale that led him to discover aberrations can sometimes be your friend.

In preparation for U.S. News World & Report’s annual best ophthalmic hospitals for 2015-which will be announced next month-we have compiled the news site’s list of the top programs from last year. These 10 hospitals were coined the best for difficult cases and procedures by at least 5% of ophthalmology respondents to U.S. News’ surveys in 2012, 2013, and 2014.

The European Medicines Agency (EMA) has granted orphan drug designation to ISTH0036, a locked nucleic acid-modified antisense oligonucleotide under development by Munich-based Isarna Therapeutics, for the prevention of scarring after glaucoma filtration surgery (GFS).